New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
05:55 EDTAMED, AMED, BONT, BONT, COST, COST, KERX, KERX, RAVN, RAVN, SYPR, SYPRCompanies reporting Before the Market Open on Tuesday, March 12
Notable companies reporting before the opening bell on Tuesday include Amedisys (AMED), Bon-Ton Stores (BONT), Costco Wholesale (COST), Keryx Biopharmaceuticals (KERX), Raven Industries (RAVN), and Sypris Solutions (SYPR).
News For AMED;BONT;COST;KERX;RAVN;SYPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
06:28 EDTKERXKeryx upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
September 30, 2015
11:23 EDTCOSTCostco expects to add 32 net new warehouses in FY16
Says expects to add 32 net new warehouses in FY16, with 18-20 of these in the U.S. Says inventories "in good shape." Sees FY16 CapEx $2.8B-$3B. Comments made on the Q4 earnings conference call. Costco is up 0.49% to $144.43 in late morning trading.
09:13 EDTCOSTOn The Fly: Pre-market Movers
HIGHER: Mediwound (MDWD), up 25.5% after being awarded a BARDA contract valued up to $112M... Novavax (NVAX), up 8.4% after RSV F vaccine meets safety endpoints in its Phase 1 clinical trial... Western Digital (WDC), up 11.7% after receiving a $3.78B equity investment by Unisplendour Corporation... Esperion Therapeutics (ESPR), up 9.9% after being upgraded to Neutral from Sell at Chardan and after JPMorgan said they still see longer-term upside in the shares... Pericom Semiconductor (PSEM), up 6.5% after Montage Technology proposes to acquire the company for $18.50 per share... Fiat Chrysler (FCAU), up 5.2% after CNBC reported that the company could launch Ferrari's IPO as soon as Friday. NOTABLE: Ralph Lauren (RL), up 6.4% after appointing Gap's (GPS) global president of Old Navy, Stefan Larsson as CEO... Gap is down 7.4%. DOWN AFTER EARNINGS: Barracuda Networks (CUDA), down 28.5%... Costco (COST), down a half a percent.
05:22 EDTCOSTCostco reports Q4 EPS $1.73, consensus $1.66
Subscribe for More Information
September 29, 2015
15:22 EDTCOSTCostco October weekly 143 straddle priced for 3.2% movement into Q4
Subscribe for More Information
10:00 EDTCOSTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:14 EDTCOSTCostco October weekly volatility elevated into Q4 and outlook
Subscribe for More Information
06:10 EDTCOSTCostco initiated with an Outperform at Telsey Advisory
Target $152.
September 25, 2015
07:22 EDTCOSTCostco October weekly volatility elevated into Q4 and outlook
Subscribe for More Information
07:06 EDTKERXKeryx price target lowered to $18 from $22 at Brean Capital
Subscribe for More Information
September 24, 2015
12:21 EDTKERXCiti says EU approval does not impact Sell on Keryx
Subscribe for More Information
09:23 EDTAMEDAmedisys management to meet with Oppenheimer
Subscribe for More Information
09:05 EDTKERXOn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
07:06 EDTKERXKeryx wins EU approval for Fexeric treatment of Hyperphosphatemia
Subscribe for More Information
06:50 EDTCOSTAmerican Express price target lowered to $70 from $85 at Jefferies
Jefferies analyst John Hecht says that even with the recent selloff, shares of American Express do not offer "compelling rewards" at current levels. Hecht believes AmEx is nearing saturation in its core demographic, the highly-affluent consumer, and views the Costco (COST) loss as a "significant challenge to overcome." American Express remains the industry leader in terms of rewards, but the gap to competitors has narrowed, Hecht tells investors in a research note. The company faces "several discrete headwinds" over the coming quarters, the analyst concludes. He cut his price target for AmEx shares to $70 from $85 and keeps a Hold rating on the name. The credit card provider closed yesterday down 8c to $75.63. Hecht has Buy ratings on card peers Discover (DFS) and Synchrony Financial (SYF).
September 23, 2015
15:16 EDTBONTGabelli lowers stake in Bon-Ton Stores to 9.72% from 10.73%

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use